Skincare Mondays | Data-Driven Dermatology Improves Patient Outcomes
Data-Driven Dermatology Improves Patient Outcomes
The use of real-world data and real-world evidence to inform health care decisions is increasing. While randomized controlled trials (RCTs) are still the gold standard for evidence-based medicine, the strict inclusion/exclusion criteria and tightly controlled conditions limit their generalizability to real-world clinical practice. Real worl …
Data-Driven Dermatology Improves Patient Outcomes
The use of real-world data and real-world evidence to inform health care decisions is increasing. While randomized controlled trials (RCTs) are still the gold standard for evidence-based medicine, the strict inclusion/exclusion criteria and tightly controlled conditions limit their generalizability to real-world clinical practice. Real worl … Continue reading "Skincare Mondays | Data-Driven Dermatology Improves Patient Outcomes"
A 55-year-old male with a medical history significant for type-2 diabetes mellitus, hypertension, and 25 pack/year smoking history undergoes percutaneous coronary intervention for an acute coronary event. He is admitted to the ICU where his exam is significant for the findings seen in the image. Lab evaluation reveals eosinophilia and acute kidney injury. What is the most likely diagnosis?
… 
Dermatologists are sounding alarm after some TikTok influencers are recommending calamine lotion as a makeup primer, claiming the hack helps improve blemishes and keeps makeup in place. It’s the latest viral beauty hack popularized on the social media platform.
Be ready for the hacks your patients may bring up in their next office visits by perusing this list of articles in the consumer press:
… 
Our new series, “The Many Faces of”, showcases side-by-side images of some of the most commonly seen dermatology conditions in an array of skin tones and briefly highlight nuances in clinical presentation. All images featured in the series are part of The Full Spectrum of Dermatology: A Diverse and Inclusive Atlas, a resource developed by co-editors Misty Eleryan, MD, MS, and Adam Friedman, … 
This malignancy is sent from your clinic to oncology and an FDA approved therapy is initiated. What is the target of this medication?
A. PD-1 receptor on tumor cells
B. PD-1 receptor on T cells
C. PD-L1 receptor on tumor cells
D. PD-L1 receptor on T cells
E. CTLA-4 receptor on tumor cells
To find out the correct answer and read the explanation, click here.
Brought … 